Business Description
Bioventus Inc
NAICS : 339112
SIC : 3845
ISIN : US09075A1088
Share Class Description:
BVS: Class ATotal Employee Number:
940Compare
Compare
Traded in other countries / regions
BVS.USA4B8.Germany Index Membership
Russell 2000Russell 3000Russell 3000Russell 2000 IPO Date
2021-02-11Description
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.44 | |||||
Debt-to-EBITDA | 2.63 | |||||
Interest Coverage | 2.58 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 1.6 | |||||
Beneish M-Score | -2.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.4 | |||||
3-Year EPS without NRI Growth Rate | 58.7 | |||||
3-Year Book Growth Rate | -19.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.55 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.47 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.9 | |||||
9-Day RSI | 68.87 | |||||
14-Day RSI | 60.27 | |||||
3-1 Month Momentum % | -2.59 | |||||
6-1 Month Momentum % | 20.91 | |||||
12-1 Month Momentum % | 35.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.69 | |||||
Quick Ratio | 1.13 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 182.96 | |||||
Days Sales Outstanding | 79.76 | |||||
Days Payable | 42.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | 8.7 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.69 | |||||
Operating Margin % | 10.45 | |||||
Net Margin % | 4.94 | |||||
EBITDA Margin % | 17.92 | |||||
FCF Margin % | 17.46 | |||||
OCF Margin % | 17.86 | |||||
ROE % | 16.78 | |||||
ROA % | 4.15 | |||||
ROIC % | 11.21 | |||||
3-Year ROIIC % | -10.76 | |||||
ROC (Joel Greenblatt) % | 48.47 | |||||
ROCE % | 10.94 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 23.85 | |||||
Forward PE Ratio | 12.54 | |||||
PE Ratio without NRI | 13.04 | |||||
Price-to-Owner-Earnings | 9.02 | |||||
PS Ratio | 1.17 | |||||
PB Ratio | 3.5 | |||||
Price-to-Free-Cash-Flow | 6.71 | |||||
Price-to-Operating-Cash-Flow | 6.56 | |||||
EV-to-EBIT | 16.58 | |||||
EV-to-EBITDA | 9.14 | |||||
EV-to-Forward-EBITDA | 9.09 | |||||
EV-to-Revenue | 1.64 | |||||
EV-to-Forward-Revenue | 1.49 | |||||
EV-to-FCF | 9.38 | |||||
Price-to-GF-Value | 1.44 | |||||
Price-to-Projected-FCF | 1.7 | |||||
Earnings Yield (Greenblatt) % | 6.03 | |||||
FCF Yield % | 15.19 |
Bioventus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioventus Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 39 days | ||
| Goldman Sachs Global Healthcare Conference | 2026-06-08 16:00 | 9.04 (+2.15%) | ||
| General meeting for 2026 | 2026-06-03 10:00 | 8.11 (+2.27%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:30 | 10.68 (+4.91%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 10.68 (+4.91%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 08:30 | 8.47 (-3.64%) | ||
| Annual report for 2025 | 2026-03-05 | 8.47 (-3.64%) |
Show
Entries
Guru Commentaries on NAS:BVS
No articles.
Press Release
Articles on Bioventus Inc
No articles.